Company Revenue Reports

Orthopedic procedure volumes improved more quickly than expected in the U.S., helping DePuy Synthes close 3Q20 down -2.6% compared to the prior year.

The company's exposure in global markets caused revenue declines of -24% in 1H20, but MicroPort launched several new products to spur future growth

The company grew in the high single digits for 1H20 as it benefited from provincial procurement tenders and the acquisition of Libeier.

The company believes it outperformed peers and took at least half a point of share in the second calendar quarter on the strength of its technology.

Despite the impact of COVID, the company forged ahead with its priorities, including expanding its U.S. business and accelerating its innovation pipeline.

The company's orthopedic sales declined -49% in 2Q20 but recovered significantly from -80% declines in April. Integra expects improvement through 2H20.

The company exited June down just -3% in its joint replacement business and expects sequential improvements to continue through 2020 and into 2021.

The company's sales improved throughout 2Q20 but exited June with declines in the mid-teens. Orthofix remains cautious about second-half unpredictability.

The company earned its seventh consecutive double-digit growth quarter in 2Q20 as it continued to drive clinical distinction and surgeon adoption.

The company exited 2Q20 with significant momentum in June and expects MACI to grow at least in the mid-single-digits for the second half of the year.